Sentence: Patients with progressive refractory NSCLC who had previously benefitted from erlotinib ( objective response or stable disease > 8weeks ) were randomized to receive treatment with either erlotinib and sorafenib ( 400 mg orally twice daily ) or sorafenib alone .
Drug combination annotation:
[{'class': 'NEG', 'spans': ['erlotinib', 'sorafenib'], 'is_context_needed': True}]